← All stocks

4D Molecular Therapeutics, Inc.

FDMT Scheduled selling only

CIK 0001650648 #2652 in the set updated 17 Sep 2026

Bought (12 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$4.65M

$3.21M on a plan · $1.44M straight out of an exercise

Sold at will

$0.00

0 of 25 sales

Net

−$4.65M

$0.00 against sales at will

By person

6 insiders · 26 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Kirn David

See Remarks

—

$4.26M (10) scheduled

−$4.26M

767,486

1.39%

$10.67M

−27.5%

Bizily Scott

Chief Legal Officer

—

$384.62K (11) scheduled

−$384.62K

8,617

0.0156%

$119.80K

−42.7%

Gupta Ashoo

VP, Finance and Controller

—

$6.73K (4) scheduled

−$6.73K

47,055

0.0852%

$654.21K

+3.1%

RA CAPITAL MANAGEMENT, L.P. entity

10% owner

—

4,563,211

8.26%

$63.44M

−10.5%

BVF PARTNERS L P/IL entity

See Explanation of Responses

—

87,911

0.1592%

$1.22M

−98.5%

THEUER CHARLES

Director

—

41,684

0.0755%

$579.53K

+28.8%

Individual transactions

Insider

Date

Role

Action

Price

Amount

THEUER CHARLES

12 Dec 2025

Director

Exercised, kept

9,333

$1.14

$10.64K

Show all 26 transactions →

What was left out

Form 4 filings counted 32

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 10

Sales straight out of an exercise 15

Sales at will 0

Transactions with no price 0

Shares from compensation/vesting 87,724

History held since 17 Dec 2020